SUPHA PHARMACHEM last traded at ₹0.25 (2026-10-13). Over the past month the stock moved -7.4%, three months the stock moved -34.2%, year the stock moved -83.6%. Its closing range over 52 weeks is ₹0.25 – ₹1.56, with the latest close 84.0% below the high.
Closing prices up to 2026-10-13.
Supha Pharmachem Ltd, formerly Remedium Lifecare, is a pharmaceutical supply-chain trader of APIs, advanced intermediates, KSMs/CRMs and other pharma chemicals for domestic and export markets. It operates through the Indian parent and Singapore subsidiary Remlife Global Pte Ltd and entered CIRP on March 17, 2026. [1]
Entity & consolidation: The Co's name changed from Remedium Lifecare to Supha Pharmachem effective December 15, 2025.[1] Its Singapore subsidiary Remlife Global, incorporated on Sep,24, contributed ₹102.48 crore revenue and ₹8.55 crore PAT in Q2 FY26 versus group revenue/PAT of ₹111.06 crore/₹8.62 crore. [2]
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Sep 2025 | 111.06 | 7.38 | 6.65 | 8.62 | 0.10 |
| Jun 2025 | 113.37 | 1.87 | 1.65 | 4.65 | 0.05 |
| Mar 2025 | 264.32 | -0.46 | -0.17 | -2.05 | -0.02 |
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2025 | 405.00 | -1.00 | 0.00 | 2.00 | 0.02 |
No AI analysis generated yet for SUPHA PHARMACHEM.
Get Free AI Stock Analysis FREE →NCLT Mumbai Approves New Resolution Professional for Supha Pharmachem Under CIRP - scanx.trade
SUPHA PHARMACHEM shares were last quoted at ₹0.25 (-3.8% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
SUPHA PHARMACHEM has a price-to-earnings (P/E) ratio of -12.50 and a price-to-book (P/B) ratio of 0.21. The industry P/E is 29.79.
The 52-week high of SUPHA PHARMACHEM is ₹1.80 and the 52-week low is ₹0.25.
The market capitalisation of SUPHA PHARMACHEM is about ₹22.05 crore.
Promoters hold about 1.13% of SUPHA PHARMACHEM.
SUPHA PHARMACHEM belongs to the Trading sector.